Novartis - Latest News [Page 1]

Ground breaking deal provides new access for treatments

Friday, 10 October 2014, 3:09 pm | Novartis

New Zealanders will gain new access to the highest number of medicines and targeted treatment areas ever agreed in a single arrangement under a deal jointly announced by PHARMAC and Novartis today. More >>

Zolvix to revolutionize sheep worm control

Tuesday, 31 March 2009, 10:59 am | Novartis

Launch of Zolvix (monepantel) set to revolutionize sheep worm control • Novartis Animal Health announces launch of Zolvix®, the first novel drench in livestock for more than 25 years. • Basel, Switzerland, March 31, 2009 – Novartis Animal Health ... More >>

Better Access to Breast Cancer Treatment in NZ

Friday, 9 June 2006, 9:51 am | Novartis

Novartis New Zealand Limited is making Femara® (letrozole) more affordable for women with the introduction of an Access Programme which will see eligible patients only pay the consumer prescription charge for their breast cancer medication. Femara was ... More >>

Cancer treatment now widely available

Wednesday, 5 January 2005, 11:55 am | Novartis

New Zealand women with advanced breast cancer who are post-menopausal, will now have access to a more effective treatment following Pharmac's announcement today that it will subsidise the drug Femara (letrozole). More >>

Elidel® Eczema Cream Fast Relief for Infants

Monday, 30 June 2003, 10:25 am | Novartis

Relief is in sight for parents driven to distraction by children itching and scratching their way through the night. New research findings show children being treated with Elidel® cream for their eczema, experience fast relief of symptoms, such as itching ... More >>

Home Sweet Habitat

Thursday, 24 April 2003, 5:19 pm | Novartis

Staff from Avondale-based Novartis New Zealand will be going hammer and tongs on Monday (eds: 28 April) as they help to build a house for a local Massey family. More >>

Encouraging Women To Be More Outspoken

Tuesday, 18 March 2003, 1:55 pm | Novartis

Encouraging women to speak up when it comes to their own health is the inspiration behind a series of free seminars being run by The New Zealand Breast Cancer Foundation, and co-sponsored by Novartis New Zealand. More >>

Data prove Glivec® is superior leukaemia treatment

Friday, 14 March 2003, 11:37 am | Novartis

Nearly three-quarters of patients achieve major treatment goal in study comparing Glivec with traditional therapy; Glivec also significantly delays disease progression More >>

Report on advertising built on erroneous figures

Wednesday, 26 February 2003, 1:53 pm | Novartis

Novartis New Zealand has strongly criticised a report to the Minister of Health “For Health or for Profit” written by Professor Toop et al that calls for the ban of direct-to-consumer (DTC) advertising of prescription drugs. More >>

Glivec For All Chronic Myeloid Leukaemia Patients

Wednesday, 5 February 2003, 8:17 am | Novartis

Novartis New Zealand is pleased to announce that its drug Glivec® (imatinib) will be fully funded as a first line treatment for newly diagnosed chronic myeloid leukaemia (CML) patients from 1 March 2003. More >>

Glivec To Be Funded For All CML And GIST Patients

Monday, 4 November 2002, 1:00 pm | Novartis

Novartis New Zealand is pleased to announce that the Board of the Pharmaceutical Management Agency (PHARMAC) of New Zealand has agreed to fund Glivec® (imatinib)* for the treatment of all phases of Philadelphia-chromosome positive chronic myeloid ... More >>

Leprosy Target Reached

Tuesday, 22 May 2001, 5:01 pm | Novartis

The World Health Organisation (WHO) announced this month that it has reached its overall target, set ten years ago, for the global ‘elimination’ of leprosy. Over 11 million patients have been cured in the past 15 years, and the number of cases ... More >>

New drug shows dramatic Leukaemia results

Tuesday, 5 December 2000, 8:56 am | Novartis

Novartis Oncology today announced that data on Glivec®, formerly STI571, will be featured in more than 50 abstracts this week at the annual meeting of The American Society of Haematology (ASH) in San Francisco. Glivec® is an investigational treatment ... More >>

Sustained Release Ritalin SR Available Next Week

Wednesday, 25 October 2000, 3:52 pm | Novartis

Novartis New Zealand announced today that the sustained release version of Ritalin (methylphenidate) will become available on 1 November 2000. From this date, the medication, which is used for the treatment of ADHD (attention deficit and hyperactivity disorder) ... More >>

New Hope For Breast Cancer Patients

Monday, 2 October 2000, 9:28 am | Novartis

Exciting new trial results could have a major impact on the lives of thousands of women with breast cancer. These results show the superioty of Novartis treatment Femara® (letrozole) over the established gold-standard tamoxifen, in the treatment ... More >>


InfoPages Links